{
  "docId": "019de06f-52ef-7226-b4e8-f3f08eb88a26",
  "docSlug": "7c032e01619eda769cbeaf2bcfe382bc",
  "documentTitle": "Pershing Square | Activist Presentation Deck | 110 slides",
  "authorId": "pershing-square",
  "authorName": "Pershing Square Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 43,
  "pageCount": 110,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "key_messages",
  "function": "present_framework",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de06f-52ef-7226-b4e8-f3f08eb88a26/43",
  "deckHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26",
  "deckJsonHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26.json",
  "deckAnchorHref": "/decks/019de06f-52ef-7226-b4e8-f3f08eb88a26#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.85,
        "x": 0.07,
        "y": 0.19
      },
      "kind": "list",
      "text": "Product mix, price, and distribution optimized for each region\nNot all products in all markets\nPartner locally where it makes sense\nSG&A zero-based for products and region\nNo pre-set percentages of revenue for sales & marketing expense\nCountry / business unit managers' compensation aligned with local business performance",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00287cd9-d46d-4e0c-90bf-bb1ef73eb01c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Highly Decentralized Operations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16d685d9-23cd-40b7-b990-ac8514dcd394",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "fb54ca07-0812-42b4-8dc3-b361d8ee5cb0",
      "evidence": "list/bullet: Product mix, price, and distribution optimized for each region Not all products in all markets Partner locally where it makes sense SG&A zero-based for products and region No pre-set percentages of revenue f",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "decentralized-operations",
      "slug": null,
      "matchId": "06e000fd-1550-4a05-925d-4e761a0d6797",
      "evidence": "The slide explicitly details a decentralized operational strategy.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 50,
      "from": 40,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3fdb7ddf-ff36-442b-a6da-1c201a07a6a6",
      "evidence": "Discussion of traditional pharma R&D model and Valeant's advantages",
      "position": 1,
      "objective": "Highlighting the cost of inaction in traditional pharma R&D",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}